The GALAXY Program: an update on studies investigating efficacy and tolerability of rosuvastatin for reducing cardiovascular risk

References

• Mackay J, Mensah GA. The Atlas of Heart Disease and Stroke. WHO, Geneva, Switzerland (2004).
   Google Scholar
• Ballantyne CM. Low-density lipoproteins and risk for coronary artery disease. Am. J. Cardiol.82, 3Q–12Q (1998).
   Web of Science ®Google Scholar
• Heart Protection Study Collaborative Group. MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomized placebo-controlled trial. Lancet360, 7–22 (2002).
   PubMed Web of Science ®Google Scholar
• Colhoun HM, Betteridge DJ, Durrington PN et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomized placebo-controlled trial. Lancet364, 685–696 (2004).
   PubMed Web of Science ®Google Scholar
• Cannon CP, Braunwald E, McCabe CH et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N. Engl. J. Med.350, 1495–1504 (2004).
   PubMed Web of Science ®Google Scholar
• Koren MJ, Hunninghake DB; ALLIANCE Investigators. Clinical outcomes in managed-care patients with coronary heart disease treated aggressively in lipid-lowering disease management clinics: the ALLIANCE study. J. Am. Coll. Cardiol.44, 1772–1779 (2004).
   PubMed Web of Science ®Google Scholar
• LaRosa JC, Grundy SM, Waters DD et al. Intensive lipid lowering with atorvastatin in patients with stable coronary disease. N. Engl. J. Med.352, 1425–1435 (2005).
   PubMed Web of Science ®Google Scholar
• Pedersen TR, Faergeman O, Kastelein JJ et al. High-dose atorvastatin vs. usual-dose simvastatin for secondary prevention after myocardial infarction: the IDEAL study: a randomized controlled trial. JAMA294, 2437–2445 (2005).
   PubMed Web of Science ®Google Scholar
• Baigent C, Keech A, Kearney PM et al. Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins. Lancet366, 1267–1278 (2005).
   PubMed Web of Science ®Google Scholar
• Wood D, De Backer G, Faergeman O, Graham I, Mancia G, Pyorala K. Prevention of coronary heart disease in clinical practice: recommendations of the Second Joint Task Force of European and other Societies on coronary prevention. Eur. Heart J.19, 1434–1503 (1998).
   PubMed Web of Science ®Google Scholar
• De Backer G, Ambrosioni E, Borch-Johnsen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Third Joint Task Force of European and other Societies on Cardiovascular Disease Prevention in Clinical Practice. Eur. J. Cardiovasc. Prev. Rehabil.10, S1–S10 (2003).
   PubMed Web of Science ®Google Scholar
• Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary of the third report of the National Cholesterol Education Program (NCEP) expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III). JAMA285, 2486–2497 (2001).
   PubMed Web of Science ®Google Scholar
• Schwandt P, Brady AJB. Achieving lipid goals in Europe: how large is the treatment gap? Expert Rev. Cardiovasc. Ther.2(3), 431–449 (2004).
   PubMedGoogle Scholar
• Foley KA, Simpson RJ Jr, Crouse JR III, Weiss TW, Markson LE, Alexander CM. Effectiveness of statin titration on low-density lipoprotein cholesterol goal attainment in patients at high risk of atherogenic events. Am. J. Cardiol.92, 79–81 (2003).
   PubMed Web of Science ®Google Scholar
• Grundy SM, Cleeman JI, Merz CN et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation110, 227–239 (2004).
   PubMed Web of Science ®Google Scholar
• Meisinger C, Loewel H, Mraz W, Koenig W. Prognostic value of apolipoprotein B and A-I in the prediction of myocardial infarction in middle-aged men and women: results from the MONICA/KORA Augsburg cohort study. Eur. Heart J.26, 271–278 (2005).
   PubMed Web of Science ®Google Scholar
• Jones PH, Davidson MH, Stein EA et al. Comparison of efficacy and safety of rosuvastatin versus atorvastatin, simvastatin, and pravastatin across doses (STELLAR trial). Am. J. Cardiol.92, 152–160 (2003).
   PubMed Web of Science ®Google Scholar
• Schuster H, Barter PJ, Stender S et al. Effects of switching statins on achievement of lipid goals: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I) study. Am. Heart J.147, 705–712 (2004).
   PubMed Web of Science ®Google Scholar
• Schuster H, Fox JC. Investigating cardiovascular risk reduction – the rosuvastatin GALAXY Programme. Expert Opin. Pharmacother.5, 1187–1200 (2004).
   PubMed Web of Science ®Google Scholar
• Gordon DJ, Probstfield JL, Garrison RJ et al. High density lipoprotein cholesterol and cardiovascular disease: four prospective American studies. Circulation79, 8–15 (1989).
   PubMed Web of Science ®Google Scholar
• Rubins HB, Robins SJ, Collins D et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high density lipoprotein cholesterol. Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N. Engl. J. Med.341, 410–418 (1999).
   PubMed Web of Science ®Google Scholar
• Boden W. High-density lipoprotein cholesterol as an independent risk factor in cardiovascular disease: assessing the data from Framingham to the Veterans Affairs High-Density Lipoprotein Intervention Trial. Am. J. Cardiol.86(Suppl.), 19L–22L (2000).
   PubMed Web of Science ®Google Scholar
• Gaw A. HDL-C and triglyceride levels: relationship to coronary heart disease and treatment with statins. Cardiovasc. Drugs Ther.17, 53–62 (2003).
   PubMed Web of Science ®Google Scholar
• Kuller LH, Tracy RP, Shaten J, Meilahn EN; MRFIT Research Group. Relation of C-reactive protein and coronary heart disease in the MRFIT nested case–control study. Am. J. Epidemiol.144, 537–547 (1996).
   PubMed Web of Science ®Google Scholar
• Danesh J, Whincup P, Walker M et al. Low grade inflammation and coronary heart disease: prospective study and updated meta-analyses. Br. Med. J.321, 199–204 (2000).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Rose L, Buring JE, Cook NR. Comparison of C-reactive protein and low-density lipoprotein cholesterol levels in the prediction of first cardiovascular events. N. Engl. J. Med.347, 1557–1565 (2002).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Pfeffer MA, Sacks F, Braunwald E. Long-term effects of pravastatin on plasma concentration of C-reactive protein. Circulation100, 230–235 (1999).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Rifai N, Lowenthal SP. Rapid reduction in C-reactive protein with cerivastatin among 785 patients with primary hypercholesterolemia. Circulation103, 1191–1193 (2001).
   PubMed Web of Science ®Google Scholar
• Albert MA, Danielson E, Rifai N, Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels. The pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. JAMA286, 64–70 (2001).
   PubMed Web of Science ®Google Scholar
• Ridker PM, Cannon CP, Morrow D et al. C-reactive protein levels and outcomes after statin therapy. N. Engl. J. Med.352, 20–28 (2005).
   PubMed Web of Science ®Google Scholar
• McKenney JM, Jones PH, Adamczyk MA, Cain VA, Bryzinski BS, Blasetto JW; STELLAR Study Group. Comparison of the efficacy of rosuvastatin versus atorvastatin, simvastatin, and pravastatin in achieving lipid goals: results from the STELLAR trial. Curr. Med. Res. Opin.19, 689–698 (2003).
   PubMed Web of Science ®Google Scholar
• Jones PH, Hunninghake DB, Ferdinand KC et al. Effect of rosuvastatin versus atorvastatin, simvastatin, and pravastatin on non-high-density lipoprotein cholesterol, apolipoproteins, and lipid ratios in patients with hypercholesterolemia: additional results from the STELLAR trial. Clin. Ther.26, 1388–1399 (2004).
   PubMed Web of Science ®Google Scholar
• Kritharides L. Reducing low-density lipoprotein cholesterol – treating to target and meeting new European goals. Eur. Heart J. Suppl.6, A12–A18 (2004).
   Web of Science ®Google Scholar
• Jones P, Watkins C, Blasetto J. Statin therapy for elevated lipid levels compared across doses to rosuvastatin (STELLAR): LDL-C goal achievement with new ATP III recommendations. Atherosclerosis110(Suppl. 6), (2005) (Abstract W16-P-040).
   Google Scholar
• Middleton A, Fuat A. Achieving lipid goals in real life: the DISCOVERY-UK study. Br. J. Cardiol.13, 72–76 (2006).
   Web of Science ®Google Scholar
• Strandberg TE, Feely J, Sigurdsson EL; DISCOVERY Study Group. Twelve-week, multicenter, randomized, open-label comparison of the effects of rosuvastatin 10 mg/d and atorvastatin 10 mg/d in high-risk adults: a DISCOVERY study. Clin. Ther.26, 1821–1833 (2004).
   PubMed Web of Science ®Google Scholar
• Gupta M, Constance C. Direct statin comparison of LDL-C values: an evaluation of rosuvastatin therapy (DISCOVERY–Canada). Atheroscler. Suppl.6, 108 (2005) (Abstract W16-P-033).
   Web of Science ®Google Scholar
• Fonseca FA, Ruiz A, Cardona-Munoz EG, Silva JM, Fuenmayor N, Marotti M; DISCOVERY-PENTA Investigators. The DISCOVERY PENTA study: a DIrect Statin COmparison of LDL-C Value – an Evaluation of Rosuvastatin therapY compared with atorvastatin. Curr. Med. Res. Opin.21, 1307–1315 (2005).
   PubMed Web of Science ®Google Scholar
• Bots AF, Kastelein JJ; DISCOVERY-Netherlands Investigators. Achieving lipid goals in real life: the Dutch DISCOVERY study. Int. J. Clin. Pract.59, 1387–1394 (2005).
   PubMed Web of Science ®Google Scholar
• Binbrek AS, Elis A, Al-Zaibag M et al. An open-label, randomized, parallel-group, multicenter, study comparing rosuvastatin with atorvastatin for the achievement of lipid goals in high-risk patients in clinical practice: the DISCOVERY-Alpha study. Curr. Ther. Res.67, 21–43 (2006).
   PubMed Web of Science ®Google Scholar
• Middleton A, Binbrek AS, Fonseca FAH, Wilpshaar W, Watkins C, Strandberg TE. Achieving 2003 European lipid goals with rosuvastatin and comparator statins in 6743 patients in real-life clinical practice: DISCOVERY meta-analysis. Curr. Med. Res. Opin.22, 1181–1191 (2006).
   PubMed Web of Science ®Google Scholar
• Clearfield MB, Amerena J, Bassand JP et al. Comparison of the efficacy and safety of rosuvastatin 10 mg and atorvastatin 20 mg in high-risk patients with hypercholesterolemia – Prospective study to evaluate the Use of Low doses of the Statins Atorvastatin and Rosuvastatin (PULSAR) [NCT00329173]. Trials7, 35 (2006).
   PubMed Web of Science ®Google Scholar
• Leiter LA, Rosenson R, Stein E et al. Efficacy and safety of rosuvastatin 40 mg versus atorvastatin 80 mg in high-risk patients with hypercholesterolemia: results of the POLARIS study. Atherosclerosis DOI:10.1016/j.atherosclerosis.2006.12.001 (2007) (Epub ahead of print).
   Google Scholar
• Leiter L, Palmer M, Sosef F; POLARIS Study Investigators. Efficacy of rosuvastatin 40 mg versus 80 mg in patients with metabolic syndrome: results from a subgroup of the POLARIS study. Diabetologia48(Suppl.), A392 (2005) (Abstract 1085).
   Google Scholar
• Pearson TA, Laurora I, Chu H, Kafonek S. The lipid treatment assessment project (L-TAP): a multi-center survey to evaluate the percentages of dyslipidemic patients receiving lipid-lowering therapy and achieving low-density lipoprotein cholesterol goals. Arch. Intern. Med.160, 459–467 (2000).
   PubMed Web of Science ®Google Scholar
• EUROASPIRE II Study Group. Lifestyle and risk factor management and use of drug therapies in coronary patients from 15 countries; principal results from EUROASPIRE II Euro Heart Survey Programme. Eur. Heart J.22, 554–572 (2001).
   PubMed Web of Science ®Google Scholar
• Faergeman O, Sosef F, Duffield E. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in high-risk patients: Results from the ECLIPSE study. Atheroscler. Suppl.7, 580 (2006) (Abstract Th-P16: 394).
   Google Scholar
• Barter P, Stender S, Morrell J, Watkins C, Kallend D. Switching to rosuvastatin from other statins has beneficial effects on apolipoprotein (apo) B and the apo B:apo A-I ratio. Atheroscler. Suppl.4, 83 (2003).
   Google Scholar
• Cheung RC, Morrell JM, Kallend D, Watkins C, Schuster H. Effects of switching statins on lipid and apolipoprotein ratios in the MERCURY I study. Int. J. Cardiol.100, 309–316 (2005).
   PubMed Web of Science ®Google Scholar
• Schuster H, Watkins C, Kallend D. Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY I): achievement of LDL-C goals with updated ATP III recommendations. Atheroscler. Suppl.6, 121, (2005) (Abstract W16-P-079).
   Google Scholar
• Ballantyne CM, Bertolami M, Hernandez Garcia HR et al. Achieving LDL cholesterol, non-HDL cholesterol, and apolipoprotein B target levels in high-risk patients: Measuring Effective Reductions in Cholesterol Using Rosuvastatin therapY (MERCURY) II. Am. Heart J.151, 975.e1–975.e9 (2006).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolaemia: a prospective, randomised, double blind trial. Circulation107, 2409–2415 (2003).
   PubMed Web of Science ®Google Scholar
• Feldman T, Koren M, Insull W Jr et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am. J. Cardiol.93, 1481–1486 (2004).
   PubMed Web of Science ®Google Scholar
• Melani L, Mills R, Hassman D et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomised, double blind trial. Eur. Heart J.24, 717–728 (2003).
   PubMed Web of Science ®Google Scholar
• Kerzner B, Corbelli J, Sharp S et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am. J. Cardiol.91, 418–424 (2003).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Weiss R, Moccetti T et al. Efficacy and safety of rosuvastatin 40 mg alone or in combination with ezetimibe in patients at high risk of cardiovascular disease (results from the EXPLORER study). Am. J. Cardiol.99, 673–680 (2007).
   PubMed Web of Science ®Google Scholar
• Ballantyne CM, Sosef F, Duffield E; EXPLORER study investigators. Rosuvastatin plus ezetimibe for achievement of low-density lipoprotein cholesterol and C-reactive protein goals: results from the EXPLORER study. Eur. Heart J.27(Suppl. 1), 943 (2006) (Abstract P5390).
   Google Scholar
• Ginsberg HN, Stalenhoef AF. The metabolic syndrome: targeting dyslipidaemia to reduce coronary risk. J. Cardiovasc. Risk10, 121–128 (2003).
   PubMedGoogle Scholar
• Ioannou GN, Weiss NS, Boyko EJ, Kahn SE, Lee SP. Contribution of metabolic factors to alanine aminotransferase activity in persons with other causes of liver disease. Gastroenterology128, 627–635 (2005).
   PubMed Web of Science ®Google Scholar
• Pyorala K, Ballantyne CM, Gumbiner B et al. Reduction of cardiovascular events by simvastatin in nondiabetic coronary heart disease patients with and without the metabolic syndrome: subgroup analyses of the Scandinavian Simvastatin Survival Study (4S). Diabetes Care27, 1735–1740 (2004).
   PubMed Web of Science ®Google Scholar
• Geluk CA, Asselbergs FW, Hillege HL et al. Impact of statins in microalbuminuric subjects with the metabolic syndrome: a substudy of the PREVEND Intervention Trial. Eur. Heart J.26, 1314–1320 (2005).
   PubMed Web of Science ®Google Scholar
• Deedwania P, Barter P, Carmena R et al. Reduction of low-density lipoprotein cholesterol in patients with coronary heart disease and metabolic syndrome: analysis of the Treating to New Targets study. Lancet368, 919–928 (2006).
   PubMed Web of Science ®Google Scholar
• Stalenhoef AF, Ballantyne CM, Sarti C et al. A Comparative study with rosuvastatin in subjects with METabolic syndrome: results of the COMETS study. Eur. Heart J.26, 2664–2672 (2005).
   PubMed Web of Science ®Google Scholar
• Deedwania PC, Hunninghake DB, Bays HE, Jones PH, Cain VA, Blasetto JW; STELLAR Study Group. Effects of rosuvastatin, atorvastatin, simvastatin, and pravastatin on atherogenic dyslipidaemia in patients with characteristics of the metabolic syndrome. Am. J. Cardiol.95, 360–366 (2005).
   PubMed Web of Science ®Google Scholar
• Stender S, Schuster H, Barter P, Watkins C, Kallend D; MERCURY I Study Group. Comparison of rosuvastatin with atorvastatin, simvastatin and pravastatin in achieving cholesterol goals and improving plasma lipids in hypercholesterolaemic patients with or without the metabolic syndrome in the MERCURY I trial. Diabetes Obes. Metab.7, 430–438 (2005).
   PubMed Web of Science ®Google Scholar
• Faergeman O, Sosef F, Duffield E. Efficacy and tolerability of rosuvastatin and atorvastatin when force-titrated in patients with the metabolic syndrome as defined by the International Diabetes Federation: results from the ECLIPSE study. Diabetologia49(Suppl. 1), 745 (2006) (Abstract 1235).
   Web of Science ®Google Scholar
• Braunwald E, Antman EM, Beasley JW; American College of Cardiology; American Heart Association. Committee on the Management of Patients With Unstable Angina. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction – summary article: a report of the American College of Cardiology/American Heart Association task force on practice guidelines (Committee on the Management of Patients With Unstable Angina). J. Am. Coll. Cardiol.40, 1366–1374 (2002).
   PubMed Web of Science ®Google Scholar
• Lablanche J-M, Tardif J-C, Benkritly A. Effects of rosuvastatin and atorvastatin on the apoB/apoA-I ratio in patients with acute coronary syndrome: the CENTAURUS study. Atheroscler. Suppl.7, 578 (2006) (Abstract Th-P16: 384).
   Web of Science ®Google Scholar
• Pitt B, Loscalzo J, Ycas J, Raichlen; LUNAR study group. Acute coronary syndromes do not lower lipid levels. J. Am. Coll. Cardiol.47(Suppl. 1), (2006) (Abstract 959–186).
   PubMed Web of Science ®Google Scholar
• Parris ES, Lawrence DB, Mohn LA, Long LB. Adherence to statin therapy and LDL cholesterol goal attainment by patients with diabetes and dyslipidemia. Diabetes Care28, 595–599 (2005).
   PubMed Web of Science ®Google Scholar
• Willich SN, Muller-Nordhorn J, Sonntag F et al. Economic evaluation of a compliance-enhancing intervention in patients with hypercholesterolaemia: design and baseline results of the open-label primary care study. Rosuvastatin based compliance initiatives to achievements of LDL-C goals (ORBITAL) study. Am. Heart J.148, 1060–1067 (2004).
   PubMed Web of Science ®Google Scholar
• Brewer HB Jr. Benefit-risk assessment of rosuvastatin 10 to 40 milligrams. Am. J. Cardiol.92(Suppl.), 23K–29K (2003).
   PubMed Web of Science ®Google Scholar
• Shepherd J, Hunninghake DB, Stein EA et al. Safety of rosuvastatin. Am. J. Cardiol.94, 882–888 (2004).
   PubMed Web of Science ®Google Scholar
• Davidson MH, Clark JA, Glass LM, Kanumalla A. Statin safety: an appraisal from the adverse event reporting system. Am. J. Cardiol.97, 32C–43C (2006).
   PubMed Web of Science ®Google Scholar
• Tonstad S, Joakimsen O, Stensland-Bugge E et al. Risk factors related to carotid intima-media thickness and plaque in children with familial hypercholesterolemia and control subjects. Arterioscler. Thromb. Vasc. Biol.16, 984–991 (1996).
   PubMed Web of Science ®Google Scholar
• Jarvisalo MJ, Jartti L, Nanto-Salonen K et al. Increased aortic intima-media thickness: a marker of preclinical atherosclerosis in high-risk children. Circulation104, 2943–2947 (2001).
   PubMed Web of Science ®Google Scholar
• Nissen S. Design and methodology of A Study To evaluate the Effect of Rosuvastatin On Intravascular ultrasound-Derived coronary atheroma burden: the ASTEROID study. Atheroscler. Suppl.4, 27 (2003) (Abstract 1P-0037).
   Google Scholar
• Nissen SE, Nicholls SJ, Sipahi I et al. Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial. JAMA295, 1556–1565 (2006).
   PubMed Web of Science ®Google Scholar
• Takayama T, Hiro T, Yamagishi M et al. Rationale and design for a study using intravascular ultrasound to evaluate effects of rosuvastatin on coronary artery atheroma in Japanese subjects: COSMOS study (COronary atherosclerosis Study Measuring effects Of rosuvastatin using intravascular ultrasound in Japanese Subjects). Circ. J.71, 271–275 (2007).
   PubMed Web of Science ®Google Scholar
• Hatsukami TS, Zhao XQ, Yuan C, Tessier JJ, Miller E, Pears JS. Study design for a randomized, double-blind trial to assess the effect of 24 months of dosing with rosuvastatin on progression of carotid artery atheroma in moderately hypercholesterolaemic patients with asymptomatic carotid stenosis. Atheroscler. Suppl.2, 47–48 (2001) (Abstract P4).
   Google Scholar
• Chu B, Hatsukami TS, Polissar NL et al. Determination of carotid artery atherosclerosis lesion type and distribution in hypercholesterolaemic patients with moderate carotid stenosis using non-invasive magnetic resonance imaging. Stroke35, 2444–2448 (2004).
   PubMed Web of Science ®Google Scholar
• Hatsukami TS, Zhao XQ, Kraiss LW et al. Assessment of rosuvastatin treatment on carotid atherosclerosis in moderately hypercholesterolaemic subjects using high-resolution magnetic resonance imaging. Eur. Heart J.26, 626 (2005).
   Google Scholar
• Shepherd J. Special report of the 75th European Atherosclerosis Society congress. Atherosclerosis181, S1–S7 (2005).
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Grobbee DE, O’Leary DH et al. Measuring Effects of intima media Thickness: an Evaluation of Rosuvastatin in subclinical atherosclerosis – the rationale and methodology of the METEOR study. Cardiovasc. Drugs Ther.18, 231–238 (2004).
   PubMed Web of Science ®Google Scholar
• Crouse JR III, Grobbee DE, O’Leary DH et al. Carotid intima-media thickness in low-risk individuals with asymptomatic atherosclerosis: baseline data from the METEOR study. Curr. Med. Res. Opin.23, 641–648 (2007). Published online 16 February 2007; DOI: 10.1185/030079907X178711
   PubMed Web of Science ®Google Scholar
• Fellström B, Zannad F, Schmieder R et al. Effects of rosuvastatin on outcomes in chronic haemodialysis patients – design and rationale of the AURORA study. Curr. Control Trials Cardiovasc. Med.6, 9 (2005).
   PubMedGoogle Scholar
• Fellström B, Zannad F, Schmieder R et al. Effect of rosuvastatin on outcomes in chronic haemodialysis patients – baseline data from the AURORA study. Atheroscler. Suppl.7, 578 (2006) (Abstract Th-P16: 387).
   Google Scholar
• Kjekshus J, Dunselman P, Blideskog M et al. A statin in the treatment of heart failure? Controlled rosuvastatin multinational study in heart failure (CORONA): study design and baseline characteristics. Eur. J. Heart Fail.7, 1059–1069 (2005).
   PubMed Web of Science ®Google Scholar
• Ridker PM; Jupiter Study Group. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein. Rationale and design of the JUPITER trial. Circulation108, 2292–2297 (2003).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Schoenhagen P et al. Effect of intensive compared with moderate lipid-lowering therapy on progression of coronary atherosclerosis: a randomized controlled trial. JAMA291, 1071–1080 (2004).
   PubMed Web of Science ®Google Scholar
• Jensen LO, Thayssen P, Pedersen KE, Stender S, Haghfelt T. Regression of coronary atherosclerosis by simvastatin: a serial intravascular ultrasound study. Circulation110, 265–270 (2004).
   PubMed Web of Science ®Google Scholar
• Shukla A, Sharma MK, Jain A, Goel PK. Prevention of atherosclerosis progression using atorvastatin in normolipidemic coronary artery disease patients – a controlled randomized trial. Indian Heart J.57, 675–680 (2005).
   PubMedGoogle Scholar
• Shepherd J, Blauw GJ, Murphy MB et al. PROspective Study of Pravastatin in the Elderly at Risk. Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial. Lancet360, 1623–1630 (2002).
   PubMed Web of Science ®Google Scholar
• Sever PS, Dahlof B, Poulter NR et al. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo-Scandinavian Cardiac Outcomes Trial – Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet361, 1149–1158 (2003).
   PubMed Web of Science ®Google Scholar
• Cohen JC, Boerwinkle E, Mosley TH Jr, Hobbs HH. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease. N. Engl. J. Med.354, 1264–1272 (2006).
   PubMed Web of Science ®Google Scholar
• Goettsch WG, Heintjes EM, Kastelein JJ, Rabelink TJ, Johansson S, Herings RM. Results from a rosuvastatin historical cohort study in more than 45 000 Dutch statin users, a PHARMO study. Pharmacoepidemiol. Drug Saf.15, 435–443 (2006).
   PubMed Web of Science ®Google Scholar
• McAfee AT, Ming EE, Seeger JD et al. The comparative safety of rosuvastatin: a retrospective matched cohort study in over 48 000 initiators of statin therapy. Pharmacoepidemiol. Drug Saf.15, 444–453 (2006).
   PubMed Web of Science ®Google Scholar
• McKenney JM (Ed.). Report of the National Lipid Association’s Statin Safety Task Force. Am. J. Cardiol.97(Suppl. 1) S1–S97 (2006).
   PubMed Web of Science ®Google Scholar
• Herregods M, Daubresse J, Michel G, Vandenhoven G, Vissers E. DISCOVERY BELUX: an open-label, randomised, multi-centre, phase IIIb, parallel group study to compare the efficacy and safety of rosuvastatin and atorvastatin in subjects with type IIa and IIb hypercholesterolaemia. Acta Cardiologica61, 235–236 (2006).
   Google Scholar
• Sipahi I, Nicholls SJ, Tuzcu EM, Nissen SE. Interpreting the ASTEROID trial. Coronary atherosclerosis can regress with very intensive statin therapy. Cleveland Clin. J. Med.73, 937–944 (2006).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Brewer HB et al. Effect of ACAT inhibition on the progression of coronary atherosclerosis. N. Engl. J. Med.354, 1253–1263 (2006).
   PubMed Web of Science ®Google Scholar
• Tardif JC, Gregoire J, L’Allier PL et al. Effects of the acyl coenzyme A:cholesterol acyltransferase inhibitor avasimibe on human atherosclerotic lesions. Circulation110, 3372–3377 (2004).
   PubMed Web of Science ®Google Scholar
• Nissen SE, Tuzcu EM, Libby P et al. Effect of antihypertensive agents on cardiovascular events in patients with coronary disease and normal blood pressure: the CAMELOT study: a randomized controlled trial. JAMA292, 2217–2225 (2004).
   PubMed Web of Science ®Google Scholar